DDInter1561 DDInter899
Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Radium Ra 223 dichloride {u} (Compound) causes {v} (Side Effect) Extravasation
Radium Ra 223 dichloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomustine
Radium Ra 223 dichloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarilumab
Radium Ra 223 dichloride {u} may lead to a major life threatening interaction when taken with {v} Abiraterone
Radium Ra 223 dichloride (Compound) causes Extravasation (Side Effect)
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Radium Ra 223 dichloride may lead to a major life threatening interaction when taken with Abiraterone